Why the study?
Does Cyclosporin A inhibit translation of IL-3 mRNA in autocrine mast cell tumor lines?
Does Cyclosporin A inhibit translation of IL-3 mRNA in autocrine mast cell tumor lines?
Cyclosporin A induces translational silencing of oncogenically induced lymphokines like IL-3 in mast cell tumors, suggesting a mechanism associated with the tumor phenotype.
Hypothesis-generating for cyclosporin A in mast cell tumors; leaves open clinical translation and should not change practice.
Translation is regulated predominantly by an interplay between cis elements at the 3' and 5' ends of mRNAs and trans-acting proteins. Cyclosporin A (CsA), a calcineurin antagonist and blocker of interleukin-2 (IL-2) transcription in T cells, was found to inhibit translation of IL-3 mRNA in autocrine mast cell tumor lines. The mechanism involved ribosome-associated poly(A) shortening and required an intact AU-rich element in the 3' untranslated region. FK506, another calcineurin inhibitor, shared the effect. The translational inhibition by CsA was specific to oncogenically induced lymphokines IL-3 and IL-4 but not to IL-6, c-jun, and c-myc, which are expressed in the nonmalignant precursor cells. Furthermore, no translational down-regulation of the mRNA was observed in IL-3-transfected precursor cells. These data suggest that translational silencing is associated with the tumor phenotype.
No takes yet. Share an insight, caveat, or question.
Nair et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: